- Do you treat patients with acute myeloid leukaemia (AML) in your Trust?
Yes
Answer:
If yes, please proceed to Question 3, if no, please answer Question 2
- Where do patients diagnosed with AML in your Trust receive treatment?
Answer: N/A
- Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period October 2023 to March 2024?
· Azacitidine monotherapy
· Low dose cytarabine (LoDAC) monotherapy
· Venetoclax + azacitidine
· Venetoclax + LoDAC
· Ivosidenib
· Intensive chemotherapy-based regimen
o Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)
· Best supportive care
· Other
o Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants
Note: this should only include patients with AML who have started first-line treatment during the 6-month window
Answer:
|
Treatment option
|
Number of newly diagnosed patients with AML starting first line treatment during the 6-month period October 2023 to March 2024
|
|
Azacitidine monotherapy
|
<5
|
|
(LoDAC) monotherapy
|
NIL
|
|
Venetoclax + azacitidine
|
NIL
|
|
Venetoclax + LoDAC
|
NIL
|
|
Ivosidenib
|
NIL
|
|
Intensive chemotherapy-based regimen
|
NIL
|
|
Best supportive care
|
<5
|
|
Other
|
NIL
|
